AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
glutamic acid 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 1310 | 56-86-0 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A non-essential amino acid naturally occurring in the L-form. Glutamic acid is the most common excitatory neurotransmitter in the CENTRAL NERVOUS SYSTEM.
|
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 1.50 | g | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 582.58 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,ACVRL1,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,CSF1R,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,IKBKB,ITK,JAK1,JAK2,JAK3,KDR,MAP2K6,MAP3K14,MAP3K21,MAP3K7,MAP4K1,MAPK10,MAPK7,MAPKAPK2,MTOR,NTRK1,NTRK2,PDK2,PDK4,PIK3CB,PIK3CD,PIK3CG,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ZAP70 | 57 | |||
| kinase-selectivity-class | AXL,BRAF,CDK9,EPHB4,GRK2,MAP2K6,MAP3K14,MAPK7,STK33,TEK,TGFBR1 | 11 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| None | FDA |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Foetal growth restriction | 79.91 | 55.88 | 15 | 252 | 9365 | 90618815 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Toxic epidermal necrolysis | 66.21 | 60.73 | 18 | 260 | 26732 | 42594325 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Toxic epidermal necrolysis | 57.65 | 44.77 | 17 | 407 | 56710 | 110532165 |
| Compartment syndrome | 57.20 | 44.77 | 11 | 413 | 5899 | 110582976 |
| Vasoplegia syndrome | 45.72 | 44.77 | 9 | 415 | 5430 | 110583445 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A09AB01 | ALIMENTARY TRACT AND METABOLISM DIGESTIVES, INCL. ENZYMES DIGESTIVES, INCL. ENZYMES Acid preparations |
| CHEBI has role | CHEBI:25512 | neurotransmitter |
| CHEBI has role | CHEBI:27027 | micronutrient |
| CHEBI has role | CHEBI:50733 | nutraceutical |
| CHEBI has role | CHEBI:75771 | mouse metabolite |
| CHEBI has role | CHEBI:76971 | <em>Escherichia coli</em> metabolite |
| CHEBI has role | CHEBI:173085 | ferroptosis inducer |
| CHEBI has role | CHEBI:78675 | fundamental metabolite |
Related Drugs by ATC class:
A09AB Acid preparations 3 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Classical phenylketonuria | contraindication | 7573000 | |
| Poisoning by digitalis glycoside | contraindication | 12876009 | |
| Sarcoidosis | contraindication | 31541009 | DOID:11335 |
| Dehydration | contraindication | 34095006 | |
| End stage renal disease | contraindication | 46177005 | DOID:784 |
| Humoral hypercalcemia of malignancy | contraindication | 47709007 | |
| Heart disease | contraindication | 56265001 | DOID:114 |
| Hypercalcemia | contraindication | 66931009 | DOID:12678 |
| Hyperparathyroidism | contraindication | 66999008 | DOID:13543 |
| Ventricular fibrillation | contraindication | 71908006 | |
| Hypercalciuria | contraindication | 71938000 | |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Kidney stone | contraindication | 95570007 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 2.97 | acidic |
| pKa2 | 3.6 | acidic |
| pKa3 | 10.35 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Adenosine receptor A3 | GPCR | IC50 | 6.21 | CHEMBL | |||||
| Glutathione reductase, mitochondrial | Enzyme | Ki | 4.37 | CHEMBL | |||||
| Glutamate receptor 1 | Ion channel | Ki | 5.87 | CHEMBL | |||||
| Glutamate receptor ionotropic, kainate 1 | Ion channel | Ki | 6.15 | CHEMBL | |||||
| Glutamate receptor 2 | Ion channel | Ki | 6.03 | CHEMBL | |||||
| Metabotropic glutamate receptor 1 | GPCR | Ki | 6.60 | CHEMBL | |||||
| Glutamate dehydrogenase 1, mitochondrial | Enzyme | WOMBAT-PK | |||||||
| Glutamate dehydrogenase 2, mitochondrial | Enzyme | WOMBAT-PK | |||||||
| Glutamate receptor ionotropic, kainate 5 | Ion channel | Ki | 6.15 | CHEMBL | |||||
| Metabotropic glutamate receptor 5 | GPCR | Ki | 6.41 | CHEMBL | |||||
| Metabotropic glutamate receptor 4 | GPCR | Ki | 5.85 | CHEMBL | |||||
| Glutamate receptor 4 | Ion channel | Ki | 6.06 | CHEMBL | |||||
| Glutamate receptor ionotropic, kainate 2 | Ion channel | Ki | 5.96 | CHEMBL | |||||
| Glutamate receptor ionotropic, kainate 3 | Ion channel | Ki | 6.10 | CHEMBL | |||||
| Metabotropic glutamate receptor 7 | GPCR | EC50 | 5.93 | CHEMBL | |||||
| Metabotropic glutamate receptor 6 | GPCR | EC50 | 5.31 | CHEMBL | |||||
| Metabotropic glutamate receptor 2 | GPCR | EC50 | 6.54 | CHEMBL | |||||
| Excitatory amino acid transporter 1 | Transporter | Ki | 4.46 | CHEMBL | |||||
| Excitatory amino acid transporter 2 | Transporter | Ki | 4.21 | CHEMBL | |||||
| Excitatory amino acid transporter 3 | Transporter | Ki | 7.29 | CHEMBL | |||||
| Glutamate receptor 3 | Ion channel | Ki | 6.60 | PDSP | |||||
| Glutamate receptor ionotropic, kainate 4 | Ion channel | Ki | 7.74 | PDSP | |||||
| Metabotropic glutamate receptor 3 | GPCR | AGONIST | Ki | 7.40 | IUPHAR | ||||
| Metabotropic glutamate receptor 8 | GPCR | AGONIST | IC50 | 5.70 | IUPHAR | ||||
| Glutamate receptor ionotropic, kainate 3 | Ion channel | Ki | 6.31 | CHEMBL | |||||
| Glutamate racemase | Enzyme | Ki | 4.55 | CHEMBL | |||||
| Metabotropic glutamate receptor 8 | GPCR | Ki | 5.47 | CHEMBL | |||||
| Metabotropic glutamate receptor 8 | GPCR | EC50 | 7.66 | CHEMBL | |||||
| Metabotropic glutamate receptor 5 | GPCR | EC50 | 5.36 | CHEMBL | |||||
| Glutamate receptor 2 | Ion channel | Ki | 6.55 | CHEMBL | |||||
| Glutamate receptor ionotropic, NMDA 1 | Ion channel | EC50 | 5.54 | CHEMBL | |||||
| Glutamate receptor ionotropic, kainate 2 | Ion channel | Ki | 5.48 | CHEMBL | |||||
| Glutamate receptor ionotropic, kainate 1 | Ion channel | Ki | 6.85 | CHEMBL | |||||
| Metabotropic glutamate receptor 4 | GPCR | EC50 | 4.92 | CHEMBL | |||||
| Metabotropic glutamate receptor 6 | GPCR | EC50 | 4.80 | CHEMBL | |||||
| Glutamate receptor 1 | Ion channel | EC50 | 4.46 | CHEMBL | |||||
| Glutamate receptor 3 | Ion channel | EC50 | 4 | CHEMBL | |||||
| Glutamate receptor 4 | Ion channel | EC50 | 4.77 | CHEMBL | |||||
| Metabotropic glutamate receptor 1 | GPCR | EC50 | 5 | CHEMBL | |||||
| Metabotropic glutamate receptor 2 | GPCR | EC50 | 5.40 | CHEMBL | |||||
| Metabotropic glutamate receptor 3 | GPCR | EC50 | 5.52 | CHEMBL | |||||
| Glutamate racemase | Enzyme | Ki | 5.24 | CHEMBL | |||||
| Excitatory amino acid transporter 4 | Transporter | IC50 | 4.89 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| D00007 | KEGG_DRUG |
| 138-15-8 | SECONDARY_CAS_RN |
| 4018681 | VANDF |
| C0061472 | UMLSCUI |
| CHEBI:16015 | CHEBI |
| GLU | PDB_CHEM_ID |
| CHEMBL575060 | ChEMBL_ID |
| DB00142 | DRUGBANK_ID |
| CHEMBL1255943 | ChEMBL_ID |
| D018698 | MESH_DESCRIPTOR_UI |
| 33032 | PUBCHEM_CID |
| 66 | INN_ID |
| 3KX376GY7L | UNII |
| 25916 | RXNORM |
| 4788 | MMSL |
| 4823 | MMSL |
| 7086 | MMSL |
| NOCODE | MMSL |
| d00487 | MMSL |
| 001113 | NDDF |
| 008075 | NDDF |
| 010581 | NDDF |
| 38909000 | SNOMEDCT_US |
| 42271003 | SNOMEDCT_US |
| 85214009 | SNOMEDCT_US |
| 1369 | IUPHAR_LIGAND_ID |
| 3KX376GY7L | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| TrophAmine | HUMAN PRESCRIPTION DRUG LABEL | 20 | 0264-1933 | SOLUTION | 0.50 g | INTRAVENOUS | NDA | 23 sections |
| Plenamine | HUMAN PRESCRIPTION DRUG LABEL | 17 | 0264-4500 | SOLUTION | 749 mg | INTRAVENOUS | ANDA | 20 sections |
| ProSol | HUMAN PRESCRIPTION DRUG LABEL | 17 | 0338-0499 | INJECTION, SOLUTION | 1.02 g | INTRAVENOUS | NDA | 21 sections |
| Clinisol | HUMAN PRESCRIPTION DRUG LABEL | 17 | 0338-0502 | INJECTION, SOLUTION | 749 mg | INTRAVENOUS | ANDA | 18 sections |
| Premasol - sulfite-free (Amino Acid) | HUMAN PRESCRIPTION DRUG LABEL | 19 | 0338-1130 | INJECTION, SOLUTION | 0.50 g | INTRAVENOUS | ANDA | 15 sections |
| Premasol - sulfite-free (Amino Acid) | HUMAN PRESCRIPTION DRUG LABEL | 19 | 0338-1131 | INJECTION, SOLUTION | 0.30 g | INTRAVENOUS | ANDA | 15 sections |
| Aminosyn-PF | HUMAN PRESCRIPTION DRUG LABEL | 18 | 0990-4178 | INJECTION, SOLUTION | 576 mg | INTRAVENOUS | NDA | 13 sections |
| Aminosyn-PF | HUMAN PRESCRIPTION DRUG LABEL | 18 | 0990-4178 | INJECTION, SOLUTION | 576 mg | INTRAVENOUS | NDA | 13 sections |
| Aminosyn-PF | HUMAN PRESCRIPTION DRUG LABEL | 18 | 0990-4179 | INJECTION, SOLUTION | 820 mg | INTRAVENOUS | NDA | 14 sections |
| Aminosyn-PF | HUMAN PRESCRIPTION DRUG LABEL | 18 | 0990-4179 | INJECTION, SOLUTION | 820 mg | INTRAVENOUS | NDA | 14 sections |
| Aminosyn II | HUMAN PRESCRIPTION DRUG LABEL | 17 | 0990-7171 | INJECTION, SOLUTION | 1107 mg | INTRAVENOUS | NDA | 19 sections |
| Aminosyn II | HUMAN PRESCRIPTION DRUG LABEL | 17 | 0990-7171 | INJECTION, SOLUTION | 1107 mg | INTRAVENOUS | NDA | 19 sections |
| Aminosyn II | HUMAN PRESCRIPTION DRUG LABEL | 17 | 0990-7172 | INJECTION, SOLUTION | 738 mg | INTRAVENOUS | NDA | 19 sections |
| Aminosyn II | HUMAN PRESCRIPTION DRUG LABEL | 17 | 0990-7172 | INJECTION, SOLUTION | 738 mg | INTRAVENOUS | NDA | 19 sections |
| Kabiven | HUMAN PRESCRIPTION DRUG LABEL | 24 | 63323-712 | INJECTION, EMULSION | 164 mg | INTRAVENOUS | NDA | 26 sections |
| Perikabiven | HUMAN PRESCRIPTION DRUG LABEL | 24 | 63323-714 | INJECTION, EMULSION | 116 mg | INTRAVENOUS | NDA | 26 sections |
| Women Secret Care | HUMAN OTC DRUG LABEL | 2 | 72530-102 | GEL | 1.74 g | TOPICAL | unapproved drug other | 8 sections |
| Stemega anti hair loss gel | HUMAN OTC DRUG LABEL | 1 | 83117-008 | GEL | 0.10 g | CUTANEOUS | unapproved drug other | 11 sections |